Navigation Links
Study Finds Ovarian Screening Tests Don't Improve Survival

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, May 18 (HealthDay News) -- New research finds that the only two tests available to screen for ovarian cancer don't reduce the average woman's risk of dying from this "silent killer."

Screening with a blood test and then a transvaginal ultrasound might even cause harm, the University of Utah study suggests, since there was a huge number of worrisome false-positive results, subsequent biopsies and resulting complications.

"I am neither surprised nor disappointed. We kind of knew that, but it's nice to have the final results of the study," said one expert, Dr. Karen Lu, a professor of gynecologic oncology at The University of Texas M.D. Anderson Cancer Center in Houston.

"This actually confirms what we've always known," added Dr. Mark Wakabayashi, chief of gynecologic oncology at City of Hope Cancer Center in Duarte, Calif.

The bottom line: there are currently no good screening techniques to detect ovarian cancer early in women who are otherwise healthy, Lu said. Unfortunately, that means that many women are diagnosed at a later stage of the illness, when it is less treatable.

"Most of these cancers are detected late, even in screening trials," Wakabayashi confirmed.

Scientists have long been investigating a blood test for a marker called CA-125, as well as transvaginal ultrasound (TVA).

To test its effectiveness, the Utah authors randomized almost 80,000 women, aged 55 to 74, to either undergo an annual CA-125 screen for six years plus TVA annually for four years, or to "usual care."

After a follow-up of up to 13 years, the researchers found no differences in ovarian cancer diagnoses or mortality rates between the two groups. There were 212 cases of ovarian cancer in the screening group, compared to 176 in the usual care group, and 118 deaths in the screening group compared to 100 in the usual care group.

The researchers plan to present their findings in June at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

Moreover, almost 3,300 women received false positive results from the screens. Almost 1,100 of these women went on to undergo surgical biopsies and 163 had some kind of serious complication, the study found.

Other screening techniques for ovarian cancer are being studied, including a trial led by Lu that looks at whether changes in CA-125 levels over time could pick up malignancies.

However, for the time being, successful screening for ovarian cancer remains elusive.

"This doesn't change anything in terms of standard of care," Lu said. "There is still no successful current effective method to screen for ovarian cancer."

"There's really nothing that's good at this point [for women at average risk]," Wakabayashi said. But, she pointed out that women at high risk for ovarian cancer, such as those carrying the malignancy-linked BRCA gene mutation, should still have their CA-125 checked and undergo ultrasounds.

More information

The U.S. National Cancer Institute has more on ovarian cancer.

SOURCES: Karen Lu, M.D., professor, gynecologic oncology, M.D. Anderson Cancer Center, University of Texas, Houston; Mark Wakabayashi, M.D., chief, gynecologic oncology, City of Hope Cancer Center, Duarte, Calif.

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Pitt researchers build a better mouse model to study depression
2. Earlier PSA Test Best Predicts Risk of Dying From Prostate Cancer: Study
3. Electronic medical records lower infant mortality, study finds
4. End-of-Life Care Differs Between U.S., Canada, Study Finds
5. Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses
6. Rise of for-profit hospice industry raises troubling questions, new study says
7. Dairy consumption does not elevate heart-attack risk, study suggests
8. Scientific study proves that goat milk can be considered as functional food
9. Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds
10. Hospitals misleading patients about benefits of robotic surgery, study suggests
11. Pills, Surgery Both Effective for Chronic Reflux: Study
Post Your Comments:
Related Image:
Study Finds Ovarian Screening Tests Don't Improve Survival
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and distributor ... Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , ... up-to-date with a version of Asterisk that will receive not only security fixes, ...
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Jobs in hospital ... healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... month of October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack ... trailer titles work with any font, giving users limitless opportunities to stylize and ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
Breaking Medicine Technology: